JP2007536933A5 - - Google Patents

Download PDF

Info

Publication number
JP2007536933A5
JP2007536933A5 JP2007513283A JP2007513283A JP2007536933A5 JP 2007536933 A5 JP2007536933 A5 JP 2007536933A5 JP 2007513283 A JP2007513283 A JP 2007513283A JP 2007513283 A JP2007513283 A JP 2007513283A JP 2007536933 A5 JP2007536933 A5 JP 2007536933A5
Authority
JP
Japan
Prior art keywords
seq
cell
antibody
pharmaceutical composition
immunoglobulin chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007513283A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007536933A (ja
JP5623690B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/016357 external-priority patent/WO2005110475A2/en
Publication of JP2007536933A publication Critical patent/JP2007536933A/ja
Publication of JP2007536933A5 publication Critical patent/JP2007536933A5/ja
Application granted granted Critical
Publication of JP5623690B2 publication Critical patent/JP5623690B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2007513283A 2004-05-10 2005-05-10 抗体 Expired - Lifetime JP5623690B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56989204P 2004-05-10 2004-05-10
US60/569,892 2004-05-10
PCT/US2005/016357 WO2005110475A2 (en) 2004-05-10 2005-05-10 Antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011121078A Division JP2011200247A (ja) 2004-05-10 2011-05-30 抗体

Publications (3)

Publication Number Publication Date
JP2007536933A JP2007536933A (ja) 2007-12-20
JP2007536933A5 true JP2007536933A5 (cg-RX-API-DMAC7.html) 2008-06-26
JP5623690B2 JP5623690B2 (ja) 2014-11-12

Family

ID=35394680

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2007513283A Expired - Lifetime JP5623690B2 (ja) 2004-05-10 2005-05-10 抗体
JP2011121078A Pending JP2011200247A (ja) 2004-05-10 2011-05-30 抗体
JP2014003463A Pending JP2014094010A (ja) 2004-05-10 2014-01-10 抗体
JP2014156064A Withdrawn JP2014223084A (ja) 2004-05-10 2014-07-31 抗体

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2011121078A Pending JP2011200247A (ja) 2004-05-10 2011-05-30 抗体
JP2014003463A Pending JP2014094010A (ja) 2004-05-10 2014-01-10 抗体
JP2014156064A Withdrawn JP2014223084A (ja) 2004-05-10 2014-07-31 抗体

Country Status (27)

Country Link
US (8) US7604800B2 (cg-RX-API-DMAC7.html)
EP (3) EP2377890B1 (cg-RX-API-DMAC7.html)
JP (4) JP5623690B2 (cg-RX-API-DMAC7.html)
KR (1) KR101256400B1 (cg-RX-API-DMAC7.html)
CN (2) CN1984680B (cg-RX-API-DMAC7.html)
AR (1) AR048781A1 (cg-RX-API-DMAC7.html)
AU (1) AU2005244072C1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0510567B8 (cg-RX-API-DMAC7.html)
CA (3) CA2907141C (cg-RX-API-DMAC7.html)
DK (1) DK1765396T3 (cg-RX-API-DMAC7.html)
EC (1) ECSP067056A (cg-RX-API-DMAC7.html)
EG (1) EG26781A (cg-RX-API-DMAC7.html)
ES (3) ES2448468T3 (cg-RX-API-DMAC7.html)
IL (3) IL178838A (cg-RX-API-DMAC7.html)
MX (1) MXPA06012986A (cg-RX-API-DMAC7.html)
MY (1) MY148646A (cg-RX-API-DMAC7.html)
NO (1) NO341844B1 (cg-RX-API-DMAC7.html)
NZ (3) NZ590690A (cg-RX-API-DMAC7.html)
PH (1) PH12015500247A1 (cg-RX-API-DMAC7.html)
PL (1) PL1765396T3 (cg-RX-API-DMAC7.html)
PT (1) PT1765396E (cg-RX-API-DMAC7.html)
RU (1) RU2482131C2 (cg-RX-API-DMAC7.html)
SG (2) SG10201606541UA (cg-RX-API-DMAC7.html)
TW (2) TWI402274B (cg-RX-API-DMAC7.html)
UA (1) UA100356C2 (cg-RX-API-DMAC7.html)
UY (1) UY28886A1 (cg-RX-API-DMAC7.html)
WO (1) WO2005110475A2 (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
US20040116333A1 (en) * 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
MY148646A (en) 2004-05-10 2013-05-15 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies
BRPI0510561A (pt) * 2004-05-11 2007-11-20 Abgenomics Corp epìtopos que induzem morte de célula t
WO2007067984A2 (en) * 2005-12-09 2007-06-14 Wyeth Neutralizing antibodies against primate psgl-1 and uses therefor
CA2741798A1 (en) * 2008-10-28 2010-05-06 Shionogi & Co., Ltd. Anti-muc1 antibody
TWI659474B (zh) * 2008-10-31 2019-05-11 Semiconductor Energy Laboratory Co., Ltd. 半導體裝置及其製造方法
GB0822011D0 (en) * 2008-12-02 2009-01-07 Queen Mary & Westfield College Treatment
IN2015DN02826A (cg-RX-API-DMAC7.html) * 2009-09-03 2015-09-11 Merck Sharp & Dohme
WO2012000094A1 (en) * 2010-06-30 2012-01-05 Mount Sinai Hospital REAGENTS AND METHODS FOR DIAGNOSING CONDITIONS ASSOCIATED WITH HYDROXYLATED HIF 1-α
ES2387156B1 (es) * 2010-12-01 2013-07-04 Universidad Autónoma de Madrid Uso de psgl-1 para el tratamiento de enfermedades inflamatorias y autoinmunes
EP2718325A4 (en) * 2011-06-13 2015-03-11 ABGENOMICS COöPERATIEF U A ANTI-PSGL-1 ANTIBODIES AND USES THEREOF
WO2013057096A1 (en) 2011-10-17 2013-04-25 Westfaelische Wilhelms-Universitaet Muenster Assessment of pml risk and methods based thereon
PL3489261T3 (pl) 2012-08-24 2021-08-16 The Regents Of The University Of California Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu
TWI595007B (zh) * 2012-09-10 2017-08-11 Neotope Biosciences Ltd 抗mcam抗體及相關使用方法
US10988528B2 (en) * 2015-08-13 2021-04-27 New York University Antibody-based molecules specific for the truncated ASP421 epitope of Tau and their uses in the diagnosis and treatment of tauopathy
WO2017120534A1 (en) * 2016-01-08 2017-07-13 Bioalliance C.V. Tetravalent anti-psgl-1 antibodies and uses thereof
WO2017214941A1 (zh) * 2016-06-16 2017-12-21 毛侃琅 一种提升SelP基因表达水平的慢病毒载体及其应用
KR20230047507A (ko) 2016-06-27 2023-04-07 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 암 치료 조합
KR20250159733A (ko) 2017-01-11 2025-11-11 브리스톨-마이어스 스큅 컴퍼니 Psgl-1 길항제 및 그의 용도
PE20250933A1 (es) 2017-03-14 2025-04-02 Five Prime Therapeutics Inc Anticuerpos de union a vista a ph acido
SG11202008593PA (en) 2018-03-21 2020-10-29 Five Prime Therapeutics Inc ANTIBODIES BINDING TO VISTA AT ACIDIC pH
AU2019301120A1 (en) 2018-07-11 2021-02-25 Bristol-Myers Squibb Company Antibodies binding to VISTA at acidic pH
KR20250024129A (ko) 2018-07-20 2025-02-18 피에르 파브르 메디카먼트 Vista의 수용체
KR20220042055A (ko) * 2019-06-04 2022-04-04 베르조 테라퓨틱스, 아이엔씨. 골수성 세포 염증성 표현형을 조절하기 위한 항-psgl-1 조성물 및 방법, 그리고 이의 용도
JP7821733B2 (ja) * 2020-01-22 2026-02-27 上海森輝医薬有限公司 エリブリン誘導体の薬物複合体、その調製方法及びその医薬的応用
JP2024540484A (ja) * 2021-11-17 2024-10-31 アルトゥルバイオ, インコーポレイテッド 抗psgl-1抗体をjak阻害剤と組み合わせて使用してt細胞媒介性炎症性疾患またはがんを治療する方法
TW202540180A (zh) * 2023-11-17 2025-10-16 美商美國全心醫藥生技股份有限公司 抗psgl-1抗體及其用途

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4704692A (en) 1986-09-02 1987-11-03 Ladner Robert C Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5378464A (en) * 1989-03-08 1995-01-03 Board Of Regents Of The University Of Oklahoma Modulation of inflammatory responses by administration of GMP-140 or antibody to GMP-140
US5464778A (en) * 1989-03-08 1995-11-07 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for P-selectin and methods of use thereof
US5690933A (en) * 1989-05-31 1997-11-25 Glaxo Wellcome Inc. Monoclonal antibodies for inducing tolerance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5709859A (en) * 1991-01-24 1998-01-20 Bristol-Myers Squibb Company Mixed specificity fusion proteins
US6309639B1 (en) * 1991-02-05 2001-10-30 The Board Of Regents Of The University Of Oklahoma Method for inhibiting an inflammatory response using antibodies to P-selectin glycoprotein ligand
US6124267A (en) * 1991-02-05 2000-09-26 Southpac Trust Internationals, Inc. O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1
US5972625A (en) * 1991-05-06 1999-10-26 The Regents Of The University Of California Assays for inhibitors of leukocyte adhesion
AU673347B2 (en) 1992-03-17 1996-11-07 Novartis Ag Genetically engineered antibodies
US5843707A (en) * 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
RU2151612C1 (ru) * 1992-12-01 2000-06-27 Протеин Дизайн Лэбс, Инк. Гуманизированный иммуноглобулин, специфичный для белка l-селектина человека
US6210671B1 (en) * 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
WO1994014836A1 (en) * 1992-12-18 1994-07-07 Centocor, Inc. Peptide inhibitors of selectin binding
DE69415154T2 (de) * 1993-01-25 1999-07-29 Dana-Farber Cancer Institute, Inc., Boston, Mass. Chimäre selektine erhältlich durch domänenaustauch und ihre verwendungen
CN1124928A (zh) * 1993-05-04 1996-06-19 赛特尔公司 P-选择蛋白抗体及其应用
WO1995014787A1 (en) * 1993-11-22 1995-06-01 Centocor, Inc. Peptide inhibitors of selecting binding
DE69630307T2 (de) 1995-08-03 2004-07-15 The Board Of Regents Of The University Of Oklahoma, Norman O-glycaninhibitoren von selectinvermittelten entzüngen
US6348581B1 (en) * 1996-10-31 2002-02-19 The Dow Chemical Company High affinity humanized anti-TAG-72 monoclonalantibodies
JP3248570B2 (ja) * 1997-10-09 2002-01-21 日本電気株式会社 半導体装置の製造方法
WO1999043353A2 (en) * 1998-02-26 1999-09-02 Boehringer Ingelheim Pharmaceuticals, Inc. Combination anti-selectin and immunosuppressant therapy
CN1342085A (zh) * 1998-10-30 2002-03-27 遗传研究所有限公司 通过p-选择素配体(psgl)拮抗剂抑制细胞素t细胞的分化
US6696620B2 (en) 2000-05-02 2004-02-24 Epicyte Pharmaceutical, Inc. Immunoglobulin binding protein arrays in eukaryotic cells
EP1289552B1 (en) * 2000-05-19 2006-03-29 The Center for Blood Research, INC. Methods for treating hemostatic disorders by soluble p-selectin
CN1124928C (zh) * 2000-07-11 2003-10-22 湛江包装材料企业有限公司 光降解双向拉伸聚丙烯薄膜的制造方法
WO2002022820A1 (en) * 2000-09-12 2002-03-21 Genetics Institute, Llc Inhibition of stenosis or restenosis by p-selectin antagonists
US20040002450A1 (en) * 2000-12-29 2004-01-01 Janette Lazarovits Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
PL366223A1 (en) 2000-12-29 2005-01-24 Bio-Technology General Corp. Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US20040001839A1 (en) * 2000-12-29 2004-01-01 Avigdor Levanon Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US6884619B2 (en) * 2001-07-17 2005-04-26 Yale University Inhibition of BEHAB cleavage and primary central nervous system (CNS) tumors
US7744888B2 (en) * 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
US20040116333A1 (en) * 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
MY148646A (en) 2004-05-10 2013-05-15 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies
BRPI0510561A (pt) * 2004-05-11 2007-11-20 Abgenomics Corp epìtopos que induzem morte de célula t
EP2718325A4 (en) 2011-06-13 2015-03-11 ABGENOMICS COöPERATIEF U A ANTI-PSGL-1 ANTIBODIES AND USES THEREOF

Similar Documents

Publication Publication Date Title
RU2487723C2 (ru) Химерные и гуманизированные антитела к cd44, которые опосредствуют цитотоксичность в отношении раковых клеток
RU2505603C2 (ru) Антитело против рецептора il-6
ES2917000T3 (es) Interferón-gamma mutante diana y usos del mismo
Valent et al. Immunotherapy-based targeting and elimination of leukemic stem cells in AML and CML
US9624276B2 (en) Peptidic chimeric antigen receptor T cell switches and uses thereof
JP2007500132A5 (cg-RX-API-DMAC7.html)
AU2025263899A1 (en) Fibroblast binding agents and use thereof
HRP20201770T1 (hr) Nova imunoterapija protiv raznih vrsta karcinoma, uključujući gastrointestinalni karcinom i gastrični karcinom
RU2019119442A (ru) Новый коньюгат аманитина
CA2451353A1 (en) Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
JP2013541335A5 (cg-RX-API-DMAC7.html)
EP2860189A3 (en) Human cytomegalovirus neutralising antibodies and use thereof
MA43330B1 (fr) Lymphocytes t transfectés et récepteurs de lymphocytes t destinés à être utilisés en immunothérapie contre des cancers
MA43328A1 (fr) Lymphocytes t transfectés et récepteurs de lymphocytes t destinés à être utilisés en immunothérapie contre des cancers
JP2015508757A5 (cg-RX-API-DMAC7.html)
EP2604693A3 (en) TNFSF single chain molecules
RU2006143686A (ru) Антитела
JP2010533498A5 (cg-RX-API-DMAC7.html)
JP2010502207A5 (cg-RX-API-DMAC7.html)
JP2006523453A5 (cg-RX-API-DMAC7.html)
NZ513498A (en) Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases
JP2012143232A5 (cg-RX-API-DMAC7.html)
FI3277321T3 (fi) T-soluimmunoglobuliinia ja musiiniproteiini 3:a (tim-3) vastaan suunnattuja vasta-aineita
JP2020500510A5 (cg-RX-API-DMAC7.html)
HRP20190799T1 (hr) Imunocitokini na bazi il-15 i sushi domene il-15r alfa